There are 2789 resources available
1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
Presenter: Jorge Hernando
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1100MO - Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Presenter: Halfdan Sorbye
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1101MO - Development of CAR T-cells for future treatment of NETs
Presenter: Barbara Mandriani
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Presenter: Joline Lim
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
517MO - Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Presenter: Natalie Cook
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
518MO - Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
Presenter: Manish Sharma
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
519MO - Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards
Presenter: Hidenori Kage
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
347MO - 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial
Presenter: Nader Sanai
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
LBA12 - Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
Presenter: Giampaolo Bianchini
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
120MO - Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
Presenter: Aranzazu Fernandez-Martinez
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast